AnaptysBio, Inc.

Contributing Author

Recent Articles by AnaptysBio, Inc.

Sep-01	Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference ANAB GlobeNewswire
May-12	Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update ANAB GlobeNewswire
May-11	Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors ANAB GlobeNewswire
May-04	Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference ANAB GlobeNewswire
Apr-24	Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim ANAB +14.84% ANAB +13.09% GlobeNewswire
Apr-20	Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations ANAB +13.22% GlobeNewswire
Mar-27	First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement ANAB -11.68% GlobeNewswire
Mar-27	Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics ANAB -11.68% GlobeNewswire
Mar-27	Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update ANAB -11.68% GlobeNewswire
Mar-03	Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results ANAB ANAB +14.61% GlobeNewswire
Feb-05	Anaptys Announces Participation at Upcoming Investor Conferences ANAB GlobeNewswire
Jan-08	Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary ANAB GlobeNewswire
Jan-06	Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference ANAB GlobeNewswire
Nov-25	Anaptys Announces Participation in December Investor Conferences ANAB GlobeNewswire
Nov-21	Anaptys Announces $100 Million Stock Repurchase Plan ANAB +5.18% GlobeNewswire
Nov-21	Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary ANAB +5.18% GlobeNewswire
Nov-10	Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis ANAB -14.30% GlobeNewswire
Nov-04	Anaptys Announces Participation in November Investor Conferences ANAB GlobeNewswire
Nov-04	Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update ANAB GlobeNewswire
Oct-29	Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation ANAB GlobeNewswire
Oct-13	Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 ANAB GlobeNewswire
Sep-29	Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 ANAB ANAB +31.59% GlobeNewswire
Sep-29	Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14 ANAB ANAB +31.59% GlobeNewswire
Aug-27	Anaptys Announces Participation in September Investor Conferences ANAB GlobeNewswire
Aug-06	Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update ANAB ANAB -9.63% GlobeNewswire
Jun-03	Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA ANAB +7.59% ANAB -9.57% GlobeNewswire
May-27	Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 ANAB GlobeNewswire
May-05	Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update ANAB GlobeNewswire

AnaptysBio, Inc.

Recent Articles by AnaptysBio, Inc.

Upgrade your Finviz experience